During most of the 20th century, neurodegenerative diseases
remained among the most enigmatic disorders of medicine. The
scientific study of these conditions was descriptive in nature,
detailing the clinical and neuropathological phenotypes associated
with various diseases, but etiologies and pathogenic mechanisms
remained obscure. Beginning in the 1970s, advances in two principal
areas biochemical pathology and molecular genetics combined to
yield powerful clues to the molecular underpinnings of several
previously "idiopathic" brain disorders. Among the classical
neurodegenerative diseases, perhaps the most rapid progress
occurred in research on Alzheimer s disease (AD). In disorders like
Huntington s disease, amyotrophic lateral sclerosis and even
Parkinson s disease, unbiased genetic screens, linkage analysis and
positional cloning have identified causative genes that
subsequently allowed the formulation of specific biochemical
hypotheses. In sharp contrast, modern research on AD developed in
the opposite order: the identification of the protein subunits of
the classical brain lesions guided geneticists to disease-inducing
genes, for example, APP, apolipoprotein E and tau. Thus, a
biochemical hypothesis of disease - that AD is a progressive
cerebral amyloidosis caused by the aggregation of the amyloid
b-protein (Ab) - preceded and enabled the discovery of
etiologies.
As progress in deciphering genotype-to-phenotype relationships
in AD accelerated during the last two decades, it became apparent
that the key challenge for understanding and ultimately treating AD
was to focus not on what was killing neurons over the course of the
disease but rather on what was interfering subtly and
intermittently with episodic declarative memory well before
widespread neurodegeneration had occurred . In other words, one
wishes to understand the factors underlying early synaptic
dysfunction in the hippocampus and then attempt to neutralize these
as soon as feasible, perhaps even before a definitive diagnosis of
AD can be made. This steady movement of the field toward
ever-earlier stages of the disorder is exemplified by the
recognition and intensive study of minimal cognitive impairment
amnestic type (MCI; . And yet patients who die with a diagnosis of
MCI have been found to already have a histopathology essentially
indistinguishable from classical AD . Therefore, even earlier
phases of this continuum are likely to become recognized, and these
might show milder histopathology and might have biochemically, but
not yet microscopically, detectable Ab species that mediate
synaptic dysfunction.
This volume serves as a record focused on bringing together
investigators at the forefront of elucidating the structure and
function of hippocampal synapses with investigators focused on
understanding how early assemblies of Ab may compromise some of
these synapses. "
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!